CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report)’s share price was up 7.8% on Friday . The company traded as high as $0.15 and last traded at $0.14. Approximately 1,923,801 shares traded hands during trading, a decline of 25% from the average daily volume of 2,548,531 shares. The stock had previously closed at $0.13.
CytoDyn Stock Performance
The firm has a fifty day moving average of $0.13 and a 200-day moving average of $0.14. The stock has a market capitalization of $168.27 million, a price-to-earnings ratio of -6.90 and a beta of 0.14.
CytoDyn (OTCMKTS:CYDY – Get Free Report) last posted its earnings results on Tuesday, October 15th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter.
About CytoDyn
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Read More
- Five stocks we like better than CytoDyn
- What Does a Stock Split Mean?
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Consumer Staples Stocks, Explained
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- 3 Tickers Leading a Meme Stock Revival
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
